How may we assist you?

Archive: "News releases"

  • French version of Pepscan website launched

    To accommodate the growing numbers of French speakers visiting our website, Pepscan has launched a French version. Our website not only serves to inform visitors about Pepscan’s offering, but also is a tool for sharing knowledge around our technologies and the benefits they bring to the scientific community. “Although peptide science – and as a result Pepscan – is a highly international and English-focused field, we want to welcome French speaking scientists in their own language. This approach fits with …

  • Passion for peptides – The people behind Pepscan

    “I’m convinced that collaboration and sharing knowledge are key in supporting our clients to be successful in the clinics.” The market for personalized neoantigen peptide cancer vaccines is very young. Currently there are about 20-30 clinical trials running worldwide and one of the first Phase I trials finished recently. Results for this new approach of cancer treatment are very promising and more studies are started up at a quick rate. Pepscan, as the manufacturer of neoantigen peptides and working with …

  • Epitope mapping – Instrumental in therapeutic antibody development

    Recently, we launched a worldwide campaign to stress the importance of epitope mapping in therapeutic antibody development. Part of this campaign is a movie featuring Dr. Dennis Flierman (Director Epitope Mapping) and Dr. Marty Wulferink (European and Dutch patent attorney). Epitope mapping not only plays a key role in functional understanding and selection of antibodies, but also in IP protection and FDA/EMA approval. Recent patent disputes have illustrated the necessity of epitope mapping in protecting a company’s interests. It is …

  • Webinar Peptide Discovery: the power of CLIPS™

    Therapeutic peptides are becoming increasingly important within the pharma industry and currently represent a market value of 28 billion USD with an annual growth rate of at least 10% over the next five years. Pepscan has developed a unique technology to discover new highly constrained peptides with enhanced affinity, selectivity and proteolytic stability suited for diagnostic and therapeutic applications. Phage display is a technology that allows for the de novo discovery of peptides against any target of interest by exploring …

  • “Pepscan has been the reliable expert partner for us with the right capacities to start our clinical journey”

    Annually thousands of pharma and biotech companies launch a clinical trial to evaluate the efficacy and safety of their potential new therapeutic or diagnostic tool. BiOrion is one of the companies that will take its first step in this clinical trajectory this year with their targeted peptide treating fibrotic diseases. Getting ready for the clinic “It is very exciting being able to enter the clinic. Therefore, we were looking for a reliable expert partner who is able to manufacture our …

  • COVID-19 Services – Patient sera epitope mapping as a tool in COVID-19 vaccine development

    Pepscan’s Precision Epitope Mapping Platform provides scientists the ability to identify the best peptide leads from large collections of patient sera and to pinpoint strain-specific or region-specific differences in immune responses. This platform is one of the tools in the search for a COVID-19 vaccine to subdue the current pandemic. “Using Pepscan’s CLIPS Precision Epitope Mapping Platform, we can screen patient and control samples to assess whether distinct epitopes are prevalent in patient sera. The addition of conformational peptide mapping …

  • Passion for peptides – The people behind Pepscan

    “Our drive to move forward combined with a positive spirit and creativity are important assets” “As an employee of Pepscan for almost 15 years, I have worked on several challenges regarding Pepscan’s continuous drive for development and improvement. I’m glad that we also overcame our latest challenge: providing our customers with on-schedule and high-quality deliveries while working under COVID-19 guidelines,” says Richard van Duinkeren, Team Lead Analytics at Pepscan. Keeping up the pace and delivery schedules As soon as the …

  • COVID-19 Services – Peptide libraries – A powerful tool for vaccine lead finding

    Benefit from an unprecedented choice of library sizes and rapid delivery times Peptide libraries are widely applied as a powerful tool in biological research. Peptide libraries provide a rapid and cost-effective solution for a broad range of bioactivity-screening purposes, like identification of critical bioactive peptides which could serve, for example, as lead for a new COVID-19-related vaccine. Pepscan is the founder of peptide library technology and has over 25 years of experience in designing, synthesizing, and utilizing custom peptide libraries. …

  • Pepscan COVID-19 Update – Facility Operational

    We would like to inform you that the Pepscan facility is operational. This allows us to proceed serving and supporting scientists in their work on amongst others diagnostic and vaccine related COVID-19 projects and treatment of cancer patients with personalized peptide vaccines. By implementing a shift-schedule and additional precautionary measures to minimize physical interaction amongst our staff, we are able to continue the production and delivery of R&D and clinical peptides so far. Our sales team works offsite, but strives …

  • Pepscan Webinar: Next generation peptide discovery

    Learn about Pepscan’s phage display technology used to discover highly constrained peptides with enhanced affinity, selectivity and proteolytic stability. April 2nd – 16.00 CEST – 10.00 ET – 7.00 PT Register here We invite you to join our upcoming webinar featuring Pepscan experts Prof. Peter Timmerman and Dr. Michael Goldflam sharing their expertise on de novo discovery of the best peptide binders for your target protein of interest.  This webinar will discuss Pepscan’s proprietary phage display CLIPSTM technology platform, which …

We use cookies to ensure that we give you the best experience on our website. We also use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on the Pepscan website. However, if you would like to, you can change your cookie settings at any time in your browser.
Cookie Policy
Find out more
Accept All Cookies
By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Cookie Settings
Accept All Cookies